← ANALYST RATINGS · TIPRANKS
Agenus (AGEN): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $27.00, the highest $40.00, the lowest $14.00. The average is +347.0% from the last price of $6.04.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 → $7.00−6.7% | Hold | +15.9% | Reiterated | 15.10.26on TipRanks 12:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.00 → $7.50−6.2% | Hold | +24.2% | Reiterated | 15.10.26on TipRanks 01:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 → $7.50−6.2% | Hold | +24.2% | Reiterated | 15.10.26on TipRanks 01:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 → $7.50−6.2% | Hold | +24.2% | Reiterated | 15.10.26on TipRanks 01:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.50 → $7.00−6.7% | Hold | +15.9% | Reiterated | 15.10.26on TipRanks 01:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 → $7.50−6.2% | Hold | +24.2% | Reiterated | 15.10.26on TipRanks 01:06 | — | |
| Michael King★★★★★★★★★★#11053 · hits 39% · avg −2.3% | Rodman & Renshaw | $19.00 | Buy | +214.6% | Initiated | 28.09.26on TipRanks 07:20 | +11.2%next day +5.1% · 5 days −8.6% | ↗ |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $14.00 | Buy | +131.8% | Reiterated | 24.09.26on TipRanks 11:35 | +1.3%next day −0.1% · 5 days −1.6% | ↗ |
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | $25.00 | Buy | +313.9% | Reiterated | 21.09.26on TipRanks 13:55 | +4.6%next day +4.5% · 5 days +14.2% | ↗ |
| Andreas Argyrides★★★★★★★★★★#1658 · hits 46% · avg +10.2% | Chardan Capital | $40.00 | Buy | +562.3% | Initiated | 18.09.26on TipRanks Sep 21 11:25 | +8.6%next day +4.6% · 5 days +7.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Agenus
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $24.50 at a price of $9.93 (+146.7%); now: $24.50 at $6.04 (+305.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.28 (from $-0.76 to $-0.01). Last quarter: $-0.01.
Sales
Next quarter’s sales estimate — $28M (from $15M to $36M). Last quarter: $35M.
Best top-analyst consensus in the sector · Healthcare
About Agenus
- CEO: Garo H. Armen
- Employees: 81
- 3 Forbes Road, Lexington, MA, 02421-7305, US
- www.agenusbio.com
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances ar
Data from the stock’s TipRanks forecast page, read 48 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗